Over the past 50 years a number of strides have been made towards the development of a Group B Streptococcal (GBS) vaccine for use in pregnant women. There are international efforts underway to complete investigational clinical trials and to determine serocorrelates of protection against invasive disease to reduce the estimated 390,000 cases and 90,000 deaths due to neonatal GBS globally.